2. Search Result
Search Result
Results for "

RhoA Inhibitor

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

1

Inhibitory Antibodies

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12646A
    Rhosin
    Maximum Cited Publications
    34 Publications Verification

    		 Ras Apoptosis Cancer
    Rhosin is a potent, specific RhoA subfamily Rho GTPases inhibitor, which specifically binds to RhoA to inhibit RhoA-GEF interaction with a Kd of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin induces cell apoptosis . Rhosin promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability .
    Rhosin
  • HY-12646
    Rhosin hydrochloride
    Maximum Cited Publications
    34 Publications Verification

    		 Ras Apoptosis Cancer
    Rhosin hydrochloride is a potent, specific RhoA subfamily Rho GTPases inhibitor. Rhosin hydrochloride specifically binds to RhoA to inhibit RhoA-GEF interaction with a Kd of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin hydrochloride induces cell apoptosis . Rhosin hydrochloride promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability .
    Rhosin hydrochloride
  • HY-145915A
    (E/Z)-ZINC09659342

    		Ras Cancer
    (E/Z)-ZINC09659342 is an inhibitor of Lbc-RhoA interaction .
    (E/Z)-ZINC09659342
  • HY-15477A
    YS-49 monohydrate
    10+ Cited Publications

    		 Akt PI3K Angiotensin Receptor Adrenergic Receptor Cardiovascular Disease Endocrinology
    YS-49 (monohydrate) is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors .
    YS-49 monohydrate
  • HY-168596
    RhoA-ROCK-IN-1

    		ROCK Apoptosis Cancer
    RhoA-ROCK-IN-1 (Compound b19) is an inhibitor of RhoA/ROCK. RhoA-ROCK-IN-1 can significantly inhibit cell proliferation, migration, and invasion, while promoting cell apoptosis. RhoA-ROCK-IN-1 demonstrates remarkable anticancer activity by inhibiting the RhoA/ROCK pathway .
    RhoA-ROCK-IN-1
  • HY-121667
    Scaff10-8

    		ROCK Cancer
    Scaff10-8, bound to RhoA, inhibits the AKAP-Lbc-mediated RhoA activation .
    Scaff10-8
  • HY-176267
    AH001

    		Ras Cardiovascular Disease
    AH001 is a orally active RhoA inhibitor, which binds a cryptic pocket proximate to GDP within RhoA with a KD of 73.16 nM. AH001 interacts with GDP, stabilizing RhoA’s interaction with its endogenous inhibitor, RhoGDIα. AH001 reduces the downstream MRTFA nuclear translocation and downregulates fibrosis/hypertrophy proteins. AH001 mitigates myocardial remodeling in multiple HF animal models, and in the 3D myocardial tissue model. AH001 exerts its cardioprotective effects through the RhoA-RhoGDIα axis, effectively inhibiting downstream RhoA activation signaling.
    AH001
  • HY-145915
    ZINC09659342

    		Ras Cancer
    ZINC09659342 (compound 13) is an inhibitor of Lbc-RhoA interaction with an IC50 of 3.6 μΜ .
    ZINC09659342
  • HY-158652
    (R)-CCG-1423

    		Ras Akt PI3K Cancer
    (R)-CCG-1423 is an inhibitor of RhoA. (R)-CCG-1423 inhibits downstream of Rho and shows specificity for SRE .
    (R)-CCG-1423
  • HY-N14739
    Dykellic acid

    		Ras Cancer
    Dykellic acid is a RhoA inhibitor. Dykellic acid can inhibit the migration and motility of B16 cells and the tube formation of HUVECs. Dykellic acid is promising for research of cancers .
    Dykellic acid
  • HY-15477
    YS-49
    10+ Cited Publications

    		 Akt PI3K Angiotensin Receptor Adrenergic Receptor Cardiovascular Disease Endocrinology
    YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells. YS-49 inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1. YS-49 is also an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors .
    YS-49
  • HY-172917
    Rho GTPase inhibitor 1

    		Ras Cancer
    Rho GTPase inhibitor 1 (compound 7) is a potent Rho GTPase inhibitor. Rho GTPase inhibitor 1 exhibits high affinity on Cdc42, Rac1 and RhoA with KDs of 151, 352, and 232 μM, respectively. Rho GTPase inhibitor 1 reduces cell migration on glioma cell line .
    Rho GTPase inhibitor 1
  • HY-109523
    Cerivastatin sodium
    2 Publications Verification

    		 HMG-CoA Reductase (HMGCR) Ferroptosis Cardiovascular Disease Cancer
    Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
    Cerivastatin sodium
  • HY-108361
    CCG-203971
    1 Publications Verification

    		 Ras Inflammation/Immunology Cancer
    CCG-203971 is a second-generation Rho/MRTF/SRF pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC50 =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC50 of 4.2 μM. Potential anti-metastasis Agent .
    CCG-203971
  • HY-129458
    Cerivastatin

    		HMG-CoA Reductase (HMGCR) Ferroptosis Cardiovascular Disease Cancer
    Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
    Cerivastatin
  • HY-P990805
    Anti-Human/Mouse GRP78 Antibody (C38)

    		HSP Metabolic Disease Cancer
    Anti-Human/Mouse GRP78 Antibody (C38) is a kind of mouse IgG2b antibody inhibitor, targeting to GRP78. Anti-Human/Mouse GRP78 Antibody (C38) inhibits RhoA, ROCK and AKT activation. Anti-Human/Mouse GRP78 Antibody (C38) can be used for the researches of cancer and metabolic disease, such as melanoma and diabetes .
    Anti-Human/Mouse GRP78 Antibody (C38)
  • HY-12649
    Y16
    5+ Cited Publications

    		 Ras Cancer
    Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP .
    Y16
  • HY-113849
    MLS-573151
    2 Publications Verification

    MLS000573151

    		 Ras Inflammation/Immunology
    MLS-573151 (MLS000573151) is a selective GTPase Cdc42 inhibitor with an EC50 of 2 μM. MLS-573151 is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42 .
    MLS-573151
  • HY-109523S
    Cerivastatin-d3 sodium

    		Ferroptosis HMG-CoA Reductase (HMGCR) Isotope-Labeled Compounds Cardiovascular Disease Cancer
    Cerivastatin-d3 sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
    Cerivastatin-d3 sodium
  • HY-139061
    Palmitoyl 3-carbacyclic phosphatidic acid

    		LPL Receptor ROCK Cancer
    Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .
    Palmitoyl 3-carbacyclic phosphatidic acid
  • HY-10341A
    Fasudil
    20+ Cited Publications

    HA-1077; AT877

    		 ROCK Calcium Channel Autophagy PKA PKC Cancer
    Fasudil (HA-1077; AT877) is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil is also a potent Ca 2+ channel antagonist and vasodilator .
    Fasudil
  • HY-10341
    Fasudil Hydrochloride
    20+ Cited Publications

    HA-1077 Hydrochloride; AT-877 Hydrochloride

    		 ROCK Calcium Channel Autophagy PKA PKC HIV Cancer
    Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca 2+ channel antagonist and vasodilator .
    Fasudil Hydrochloride
  • HY-10341C
    Fasudil dihydrochloride
    20+ Cited Publications

    HA-1077 dihydrochloride; AT-877 dihydrochloride

    		 Calcium Channel ROCK PKA PKC Autophagy HIV Cancer
    Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil dihydrochloride is also a potent Ca 2+ channel antagonist and vasodilator .
    Fasudil dihydrochloride
  • HY-10341B
    Fasudil hydrochloride semihydrate

    HA-1077 hydrochloride semihydrate; AT877 hydrochloride semihydrate

    		 ROCK Calcium Channel Autophagy HIV PKA PKC Cancer
    Fasudil (HA-1077; AT877) hydrochloride semihydrate is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil hydrochloride semihydrate is also a potent Ca 2+ channel antagonist and vasodilator .
    Fasudil hydrochloride semihydrate
  • HY-10341D
    Fasudil mesylate

    HA-1077 mesylate; AT-877 mesylate

    		 ROCK Calcium Channel Autophagy PKA PKC Cancer
    Fasudil (HA-1077; AT877) mesylate is a nonspecific and orally active RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil mesylate is also a potent Ca 2+ channel antagonist and vasodilator .
    Fasudil mesylate
  • HY-P2325
    Exoenzyme C3, clostridium botulinum

    		Biochemical Assay Reagents ROCK Neurological Disease Metabolic Disease
    Exoenzyme C3, clostridium botulinum, is a mono-ADP-ribosylating enzyme. Exoenzyme C3, clostridium botulinum specifically modifies RhoA, B, and C by transferring ADP-ribose to them, thereby inactivating these GTPases. Exoenzyme C3, clostridium botulinum can induce neuronal axonal and dendritic growth, inhibit macrophage migration, and regulate cytoskeletal dynamics. Exoenzyme C3, clostridium botulinum can be used in the research of spinal cord injury and diabetic painful neuropathy .
    Exoenzyme C3, clostridium botulinum
  • HY-10341R
    Fasudil Hydrochloride (Standard)

    HA-1077 Hydrochloride (Standard); AT-877 Hydrochloride (Standard)

    		 Reference Standards ROCK Calcium Channel Autophagy PKA PKC HIV Cancer
    Fasudil (Hydrochloride) (Standard) is the analytical standard of Fasudil (Hydrochloride). This product is intended for research and analytical applications. Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca 2+ channel antagonist and vasodilator .
    Fasudil Hydrochloride (Standard)
  • HY-115376
    Z62954982

    ZINC08010136

    		 Ras Inflammation/Immunology
    Z62954982 (ZINC08010136) is a potent, selective and cell-permeable Rac1 (IC50=12 μM) inhibitor that is 4 times more effective than NSC23766 (HY-15723A) (IC50=50 μM). Z62954982 disrupts the Rac1/Tiam1 complex and decreases cytoplasmic levels of active Rac1 (GTP-bound Rac1), without affecting the activity of other Rho GTPases (such as Cdc42 or RhoA) .
    Z62954982
  • HY-117548
    UNC1062
    2 Publications Verification

    		 TAM Receptor Apoptosis p38 MAPK ERK PI3K Akt JAK STAT Cardiovascular Disease Cancer
    UNC1062 is a highly selective tyrosine kinase (MERTK) inhibitor with an IC50 of 1.1 nM (Morrison Ki = 0.33 nM). UNC1062 exhibits good selectivity for the TAM family (TYRO3 IC50 = 60 nM, AXL IC50 = 85 nM). UNC1062 exhibits significant anti-proliferative effects and induces apoptosis in various cancer models (such as melanoma, gastric cancer, and acute myeloid leukemia). UNC1062 inhibits multiple pathways, including MAPK/ERK, PI3K/AKT and JAK/STAT and affects the motility of head and neck squamous cell carcinoma (HNSCC) cells through the RhoA signaling pathway. UNC1062 inhibits macrophage efferocytosis, and it suitable for research on atherosclerosis .
    UNC1062
  • HY-I0400
    N-Acetylneuraminic acid
    3 Publications Verification

    NANA; Lactaminic acid

    		 Tyrosinase Ras Influenza Virus Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    N-Acetylneuraminic acid
  • HY-135457
    JMS-053
    3 Publications Verification

    		 Phosphatase STAT Ras Cancer
    JMS-053 is an efficient and reversible PTP4A3 inhibitor, with an IC50 value of 18 nM. JMS-053 demonstrates broad PTP4A inhibitory activity with IC50s of 50 nM and 53 nM for PTP4A1 and PTP4A2, respectively. JMS-053 exhibits IC50 values of 92.6 nM and 207.6 nM for CDC25B and DUSP3, respectively. JMS-053 can effectively inhibit the activity of PTP4A3, inhibit tumor cell proliferation and migration through multiple mechanisms such as interfering with RhoA and STAT3/p38 signaling pathway. JMS-053 can be used for the study of cancers such as ovarian cancer, breast cancer and colon cancer .
    JMS-053
  • HY-I0400R
    N-Acetylneuraminic acid (Standard)

    NANA (Standard); Lactaminic acid (Standard)

    		 Reference Standards Tyrosinase Ras Influenza Virus Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    N-Acetylneuraminic acid (Standard) is the analytical standard of N-Acetylneuraminic acid. This product is intended for research and analytical applications. N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    N-Acetylneuraminic acid (Standard)
  • HY-105284R
    Sulopenem (Standard)

    CP-70429 (Standard)

    		 Beta-lactamase Reference Standards Bacterial Antibiotic Infection
    N-Acetylneuraminic acid (Standard) is the analytical standard of N-Acetylneuraminic acid. This product is intended for research and analytical applications. N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    Sulopenem (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: